OECD 488: Big Blue® In Vivo Assay
Gentronix offers the Big Blue® Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays to support mutagenicity assessment in compliance with the OECD 488 guideline.
SERVICE INFORMATION
Transgenic Rodent (TGR) studies play a key role in assessing in vivo mutagenicity risk for mate rials with pre-existing data that indicates a potential genotoxicity risk to human health and the environment. Scantox is now the sole global provider of the Big Blue® transgenic rat and mouse models, offering the assay in a wide array of tissue types. The Big Blue® rodent models are completely transfected with bacteriophage or plasmid DNA, which carry mutational sequences that are susceptible to mutations. After 28 days of test substance administration, the test system DNA is extracted from animal tissues and transferred to a bacterial host. Positive selection methods are employed to detect evidence of mutation and establish mutant frequency.
We presented the establishment of Big Blue® laboratory proficiency at SOT 2023. To view our poster, click here.
| Study Format | Single Mutagenicity test |
| Tester Strains | Big Blue® rat Fischer 344 Big Blue® mouse C57BL/6 |
| OECD Guideline | 488 |
| Study Design | 28-day dosing period + 3-day treatment free period or 28-day dosing period + 28-day treatment free period |
| Tissues analysed | Liver, duodenum, glandular stomach, bone marrow, lung, kidney & germ cell. Other tissues available upon request. |
| Mutation Endpoint | cII mutations within λ bacteriophage shuttle vector |